The estimated Net Worth of Wetteny Joseph is at least $3.4 Million dollars as of 30 June 2024. Mr. Joseph owns over 28,026 units of Catalent stock worth over $1,126,649 and over the last 9 years he sold CTLT stock worth over $541,573. In addition, he makes $1,736,330 as Chief Financial Officer and Senior Vice President at Catalent.
Sign up
Mr. Joseph CTLT stock SEC Form 4 insiders trading
Wetteny has made over 6 trades of the Catalent stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 28,026 units of CTLT stock worth $1,671,190 on 30 June 2024.
The largest trade he's ever made was exercising 28,026 units of Catalent stock on 30 June 2024 worth over $1,671,190. On average, Wetteny trades about 1,013 units every 39 days since 2015. As of 30 June 2024 he still owns at least 18,894 units of Catalent stock.
You can see the complete history of Mr. Joseph stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wetteny Joseph biography
Wetteny Joseph is Chief Financial Officer, Senior Vice President of the Company. Mr. Joseph has served as our Senior Vice President and Chief Financial Officer since February 2018. He first joined us in 2008 as our Vice President and Corporate Controller, and held senior finance positions until October 2015, when he was named President, Clinical Supply Services, one of our principal business units. Before joining us, Mr. Joseph held a variety of senior financial positions at the industrial distribution company HD Supply, including as CFO of its $1.2 billion plumbing and HVAC business unit. He also served as Corporate Controller for Hughes Supply, a Fortune 500, NYSE-listed company that was acquired by Home Depot and became part of HD Supply. In his early career, Mr. Joseph spent six years at PricewaterhouseCoopers as an auditor and strategic financial advisor across a variety of industries. Mr. Joseph holds both a master’s and bachelor’s degrees in accounting from Florida Atlantic University and is a Certified Public Accountant.
What is the salary of Wetteny Joseph?
As the Chief Financial Officer and Senior Vice President of Catalent, the total compensation of Wetteny Joseph at Catalent is $1,736,330. There are 6 executives at Catalent getting paid more, with John Chiminski having the highest compensation of $8,514,990.
How old is Wetteny Joseph?
Wetteny Joseph is 47, he's been the Chief Financial Officer and Senior Vice President of Catalent since 2018. There are 23 older and 3 younger executives at Catalent. The oldest executive at Catalent Inc. is Rolf Classon, 75, who is the Independent Director.
What's Wetteny Joseph's mailing address?
Wetteny's mailing address filed with the SEC is C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY, NJ, 07054.
Insiders trading at Catalent
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius, and Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
What does Catalent do?
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
What does Catalent's logo look like?
Complete history of Mr. Joseph stock trades at Ashland Inc, Catalent, and Zoetis Inc
Catalent executives and stock owners
Catalent executives and other stock owners filed with the SEC include:
-
John Chiminski,
Chairman of the Board, Chief Executive Officer -
Peter Buzy,
Chairman - Gene Therapy -
Alessandro Maselli,
Pres & COO -
John R. Chiminski,
Chairman & CEO -
Alessandro Maselli,
President, Chief Operating Officer -
Jonathan Arnold,
President - Oral Drug Delivery Solutions -
Wetteny Joseph,
Chief Financial Officer, Senior Vice President -
Steven Fasman,
Senior Vice President, General Counsel and Corporate Secretary -
Steven L. Fasman,
Sr. VP, Gen. Counsel & Corp. Sec. -
Karen A. Flynn,
Chief Commercial Officer -
Thomas P. Castellano,
Sr. VP & CFO -
Jack Stahl,
Lead Independent Director -
John Greisch,
Independent Director -
Donald Morel,
Independent Director -
Gregory Lucier,
Independent Director -
Rosemary Crane,
Independent Director -
Rolf Classon,
Independent Director -
J. Martin Carroll,
Independent Director -
Christa Kreuzburg,
Independent Director -
Madhavan Balachandran,
Independent Director -
Peter Zippelius,
Independent Director -
Z Mahdavi,
Vice President of Open Innovation, Biologics, Cell and Gene Therapy -
Jim Walter,
Vice President of Operations for its Oral and Specialty Delivery business -
Scott Gunther,
Senior Vice President - Quality & Regulatory Affairs -
Mike Grippo,
Senior Vice President - Strategy and Corporate Development -
Charles Lickfold,
Senior Vice President, Chief Information Officer -
Ricardo Pravda,
Chief Human Resource Officer, Senior Vice President -
Ricci Whitlow,
President - Clinical Supply Services -
Aristippos Gennadios,
President - Softgel Technologies -
Mario Gargiulo,
Region President, Biologics – Europe -
Karen Flynn,
President - Biologics and Chief Commercial Officer -
Manja Boerman,
President - Cell & Gene Therapy -
Ricardo Pravda,
Sr. VP & Chief HR Officer -
Michael J. Grippo,
Sr. VP of Strategy & Corp. Devel. -
Paul Surdez,
VP of Investor Relations -
Julien Meissonnier,
VP & Chief Scientific Officer -
Ricky Hopson,
VP & Chief Accounting Officer -
Sharon Johnson,
See Remarks -
Uwe Roehrhoff,
Director -
James Quella,
Director -
Management Associates V L.L...,
-
Melvin D Booth,
Director -
Matthew M Walsh,
See Remarks -
Christine Dolan,
See Remarks -
Stephen Leonard,
See Remarks -
Michael J Grippo,
SVP, Strategy & Corp. Dev. -
William Downie,
See Remarks -
Lance Miyamoto,
See Remarks -
Barry Littlejohns,
President, Biologics & SDD -
Paul W Jr Hegwood,
President, CSS -
Scott Houlton,
See Remarks -
Healthcare Partners L.L.C. ...,
10% owner -
Nielsen Kurt,
See Remarks -
Michael J Barber,
Director -
Michael Hatzfeld,
Chief Accounting Officer -
Thomas P Castellano,
SVP, Chief Financial Officer -
Frank A Damelio,
Director -
Michelle R Ryan,
Director -
Stephanie Okey,
Director -
Thomas W Hawkeswood,
Pres. Pharma Prod Delivery Div -
Karen Murphy Santiago,
VP & Chief Accounting Officer -
Patricia Hunt,
Pres. Consumer Health Div -
Michael A. Riley,
Pres. Bio Product Delivery Div -
Lorenzo Carletti,
SVP Global Ops Ph & Cons Hlth -
Kay A Schmidt,
SVP, Enterprise Functions -
Lisa Evoli,
SVP, Chief HR Officer -
Matti Masanovich,
SVP, Chief Financial Officer -
Ricardo Zayas,
SVP, Operations, Biologics NA -
Joseph Anthony Ferraro,
SVP, General Counsel, CCO -
Steven Barg,
Director -
David Mc Erlane,
Group President, Biologics -
Ricky Hopson,
Pres. BioProduct Delivery, CoS